Pharmacogenetic analysis of clinically relevant genetic polymorphisms

Clinical Infectious Diseases

Volumn 41, Issue SUPPL. 7, 2005, Pages

  McLeod, Howard L ^a,b  

^a Washington University in St Louis School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANALGESIC AGENT; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; DNA; SEDATIVE AGENT;

CONFERENCE PAPER; CRITICAL ILLNESS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

COST CONTROL; CRITICAL CARE; DRUG THERAPY; GENETIC MARKERS; GENOME, HUMAN; HUMANS; INTENSIVE CARE UNITS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 27744489705     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431995     Document Type: Conference Paper

References (26)

1. Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov 2004; 3:88-93.
2. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49.
3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-37.
4. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm 2002; 59:2061-9.
5. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41:101-21.
6. Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 2002; 20:174-9.
7. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004; 429:446-52.
8. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-33.
9. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27:234-6.
10. Kwok PY, Chen X. Detection of single nucleotide polymorphisms. Curr Issues Mol Biol 2003; 5:43-60.
11. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-8.
12. Voora D, McLeod HL, Eby C, Gage BF. Use of pharmacogenetics to guide warfarin therapy. Drugs Today (Bare) 2004; 40:247-57.
13. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26:186-91.
14. Cariou A, Chiche JD, Charpentier J, Dhainaut JF, Mira JP. The era of genomics: impact on sepsis clinical trial design. Crit Care Med 2002; 30:S341-8.
15. Alston TA, Lowenstein E. Black and white and read all over: the human genome. Crit Care Med 2004; 32:1073-4.
16. Tabrizi AR, Zehnbauer BA, Freeman BD, Buchman TG. Genetic markers in sepsis. J Am Coll Surg 2001; 192:106-17.
17. Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med 2004; 32:569-79.
18. Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis 2004; 39:98-106.
19. Lanfear DE, Marsh S, Cresci S, Spertus JA, McLeod HL. Frequency of compound genotypes associated with beta-blocker efficacy in congestive heart failure. Pharmacogenomics 2004; 5:553-8.
20. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-30.
21. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350:2558-63.
22. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334:1090-4.
23. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-5.
24. Saleh M, Vaillancourt JP, Graham RK, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429:75-9.
25. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:S313-9.
26. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22:481-93.